PEBC Part I (MCQ) · Competency 1A Clinical Care (about 50% of Part I)
Respiratory items test the CTS 2021 asthma and 2023 COPD updates, inhaler technique, exacerbation action, smoking cessation pharmacotherapy and allergic rhinitis, often in patient cases with control criteria to interpret.
1A Clinical Care2 min read6 sections
Checked against the CTS 2021 asthma guideline update (Can J Respir Crit Care Sleep Med 2021;5:348); CTS 2023 COPD pharmacotherapy update (2023;7:173); CAN-ADAPTT smoking cessation guideline (2011); Health Canada product monographs; checked 13 Oct 2026. Not affiliated with or endorsed by The Pharmacy Examining Board of Canada (PEBC).
Expect case sets that ask you to judge control, check adherence and technique before stepping up, and choose cessation therapy for a patient with comorbidities.
Check adherence (refill history) and technique before escalating.
Spacer with mask for young children; mouthpiece from about age 6.
Action plan: peak flow below about 60% of best with escalating reliever use needs oral steroid and same-day care.
Continue controller therapy in pregnancy; budesonide has reassuring data.
Every note. Every question. One pass.
4 more sections of this note are part of Premium.
From about C$16.58/mo on the Until-you-pass pass (12 months)
Educational practice material for exam preparation only. Not medical advice and not a substitute for current product monographs, clinical guidelines or professional judgement. Questions have not yet been reviewed by a licensed pharmacist.
